Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants

Perdrizet, Johnna; Santana, C.F.S.D.; Senna, T.; Alexandre, R.F.; Almeida, Rodrigo Sini de; Spinardi, Júlia; Wasserman, Matt

doi:10.1080/21645515.2020.1809266

Cited by 9 publications

(7 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The model structure was based on various previously published decision-analytic forecasting models [6][7][8][9][10][11][12][13] that leverage historical real-world surveillance data to predict future clinical and economic outcomes. Specifically, the model prospectively predicts age-specific incidence trends by individual serotype or grouped serotypes based on observed retrospective incidence and serotype dynamics.…”

Section: Model Structurementioning

confidence: 99%

Cost-Effectiveness Analysis of the South African Infant National Immunization Program for the Prevention of Pneumococcal Disease

et al. 2023

View full text Add to dashboard Cite

Introduction Pneumococcal disease, which presents a substantial health and economic burden, is prevented through pneumococcal vaccination programs. We assessed the impact of switching from a 13-valent-based (PCV13) to lower 10-valent-based (PCV10-GlaxoSmithKline [GSK] or PCV10-Serum Institute of India [SII]) or higher-valent (PCV15 or PCV20) vaccination programs in South Africa. Methods A previously published decision-analytic model was adapted to a South African setting. Historical invasive pneumococcal disease (IPD) incidence data were used to project IPD incidence over time for each vaccination program on the basis of serotype coverage. Historical incidence (IPD, pneumonia, otitis media), mortality, costs, and utilities were obtained from the published literature. Cases of disease, direct medical costs (i.e., vaccination, IPD, pneumonia, and otitis media costs) (in 2022 South African rands), life-years, quality-adjusted life-years (QALY), and incremental cost per QALY were estimated over a 5- and 10-year horizon for PCV13 and the PCV10 vaccines. Additionally, a public health impact analysis was conducted comparing PCV13, PCV15, and PCV20. Results Continuing use of PCV13 would substantially reduce disease incidence over time compared with switching to either of the PCV10 lower-valent vaccines. Cases of IPD were reduced by 4.22% and 34.70% when PCV13 was compared to PCV10-GSK and PCV10-SII, respectively. PCV13 was also found to be cost saving over 5- and 10-year time horizons compared with PCV10-SII and to be cost-effective over a 5-year time horizon and cost-saving over a 10-year time horizon compared with PCV10-GSK. PCV20 was consistently estimated to prevent more cases than the PCV10 vaccines, PCV13, or PCV15. Conclusions Switching from a higher-valent to a lower-valent vaccine may lead to disease incidence re-emergence caused by previously covered serotypes. Maintaining PCV13 was estimated to improve public health further by averting additional pneumococcal disease cases and saving more lives and also to reduce total costs in most scenarios. Higher-valent PCVs can achieve the greatest public health impact in the pediatric vaccination program in South Africa. Supplementary Information The online version contains supplementary material available at 10.1007/s40121-023-00767-4.

show abstract

Section: Model Structurementioning

confidence: 99%

Cost-Effectiveness Analysis of the South African Infant National Immunization Program for the Prevention of Pneumococcal Disease

et al. 2023

View full text Add to dashboard Cite

show abstract

“…We used a previously developed decision-analytic model (see Supplementary Material) to estimate the public clinical and economic impact of a switch from a PCV10-based infant vaccination program to a PCV13-based program in Belgium [17]. This model framework and assumptions have been detailed in previous publications [6,8,9,10,15,17]. Briefly, we used observed IPD surveillance data by serotype from periods with and without serotype-specific vaccine coverage to project disease incidence with either PCV13 or PCV10.…”

Section: Model Structurementioning

confidence: 99%

“…Previously, a decision-analytic model was developed to predict the clinical and economic benefit of maintaining use of PCV13 compared with switching to PCV10 in countries where PCV13 was being used as part of routine infant immunization [6,8,9,10,15,17]. However, limited real-world evidence was available at the time of model development to validate the projections from those analyses.…”

Section: Introductionmentioning

confidence: 99%

Validation of a Novel Forecasting Method for Estimating the Impact of Switching Pneumococcal Conjugate Programs: Evidence from Belgium

et al. 2021

View full text Add to dashboard Cite

Introduction: Since 2010, 10-valent (PCV10) and 13-valent pneumococcal conjugate vaccines (PCV13) have been available as part of infant national immunization programs. Belgium is as one of the few countries that implemented PCV13 (2007)(2008)(2009)(2010)(2011)(2012)(2013)(2014)(2015), switched to PCV10 (2015)(2016)(2017)(2018) and then switched back to PCV13 (2018-present) after observing increases in disease. We assessed the impacts of both historical and prospective PCV choice in the context of the Belgian health care system and used this experience to validate previously developed economic models. Methods: Using historical incidence (2007)(2008)(2009)(2010)(2011)(2012)(2013)(2014)(2015)(2016)(2017)(2018) of pneumococcal disease for Belgian children aged \ 16 years, observed invasive pneumococcal disease (IPD) trends from surveillance data were used to estimate future disease in a given PCV13-or PCV10-based program. We compared observed incidence data with two modeled scenarios: (1) the 2015 switch to PCV10 and (2) a hypothetical continuation of PCV13 in 2015. Finally, we explored the potential impact of PCV choice from 2019 to 2023 by comparing three scenarios: (3) continued use of PCV10; (4) a switch back to PCV13;(5) a hypothetical scenario in which Belgium never switched from PCV13. Results: Model predictions underestimated observed data from 2015 to 2018 by 100 IPD cases among ages \ 16 years. Comparing observed data with scenario 2 suggests that PCV13 would have prevented 105 IPD cases from 2015 to 2018 compared with PCV10. Switching to PCV13 in 2019 would avert 625 IPD cases through 2023 compared with continuing PCV10. Scenario never switching from PCV13 would have resulted in a reduction of 204 cases from 2016 to 2023 compared with switching to PCV10 and switching back to PCV13. Conclusion:The findings from this study suggest that previously published modeling results of PCV13 versus PCV10 in other countries may have underestimated the benefit of PCV13. These results highlight the importance of continually protecting against vaccine-preventable pneumococcal serotypes.

show abstract

“…We have read with interest the manuscript published by Human Vaccines and Immunotherapeutics entitled “Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PHiD-CV) with the 13-valent pneumococcal conjugate vaccine (PCV-13) in Brazil infants” (Perdrizet et al). 1 Although the study addresses an important topic, we believe the article may create confusion based on the assumptions used for the simulation and have unintended negative impact on public health decisions.…”

mentioning

confidence: 99%

“… 7 In the analytical framework used by Perdrizet et al, comparisons between the model’s estimations and past data observations are not presented and therefore there is limited explanation on how well trend regressions could predict historical and future data. 1 In addition, serotype-specific regression analysis was used to forecast future disease trends based on serotype behaviors observed in the USA, UK, Canada, and Quebec in order to reflect PCV13 infant vaccination effects. The pneumococcal serotypes behavior in those countries cannot be explained solely by the serotype content of the respective PCVs.…”

mentioning

confidence: 99%

Response to article by Johnna Perdrizet et al.,“Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants”

Gómez¹,

Pinto

Guevara³

et al. 2021

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants

Abstract: (2020): Costeffectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants, Human Vaccines & Immunotherapeutics,

Cited by 9 publications

References 36 publications

Cost-Effectiveness Analysis of the South African Infant National Immunization Program for the Prevention of Pneumococcal Disease

Cost-Effectiveness Analysis of the South African Infant National Immunization Program for the Prevention of Pneumococcal Disease

Validation of a Novel Forecasting Method for Estimating the Impact of Switching Pneumococcal Conjugate Programs: Evidence from Belgium

Response to article by Johnna Perdrizet et al.,“Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants”

Contact Info

Product

Resources

About